Jaeger, Dirk

Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., et al. (2017) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 765

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors

Alvarez, M. J., Subramaniam, P. S., Tang, L. H., Grunn, A., Aburi, M., Rieckhof, G., Komissarova, E. V., Hagan, E. A., Bodei, L., Clemons, P. A., et al. (2018) · Nature Genetics

Neuroendocrine Tumor Research AdvancesNeuroblastoma Research and Treatments

Cited by 210

Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs. investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177

Diaz, L. A., Le, D. T., Yoshino, T., Andre, T., Bendell, J. C., Koshiji, M., Zhang, Y., Kang, S. P., Lam, B., & Jaeger, D. (2017) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 11